Endocrine-related Cancer
Overview
Endocrine-related Cancer is a peer-reviewed journal that focuses on the study of cancers originating from endocrine glands or hormone-producing cells. It covers a wide range of topics including molecular biology, genetics, epidemiology, diagnosis, and treatment of endocrine-related cancers. The journal aims to provide valuable insights into the mechanisms underlying these cancers and to promote advancements in their management and prevention.
Details
Details
Abbr.
Endocr Relat Cancer
Start
1994
End
Continuing
Frequency
Quarterly
p-ISSN
1351-0088
e-ISSN
1479-6821
Country
United Kingdom
Language
English
Specialties
Oncology
Endocrinology
Endocrinology
Metrics
Metrics
h-index / Ranks: 1490
146
SJR / Ranks: 2373
1331
CiteScore / Ranks: 1426
10.00
JIF / Ranks: 2352
3.9
Recent Articles
11.
Solar Vasconcelos J, Nunez Rodriguez J, Zaidi A, Krishnan T, Jafari H, Gill S, et al.
Endocr Relat Cancer
. 2025 Feb;
32(4).
PMID: 39928294
Advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) constitute a heterogeneous group of incurable cancers. Lenvatinib is an oral multiple kinase inhibitor that showed activity in grade 1/2 GEP-NENs in the phase II...
12.
Ponder B, Kurzawinski T, Kurzawinski T
Endocr Relat Cancer
. 2025 Feb;
32(4).
PMID: 39913251
No abstract available.
13.
Kim D, Kang M, Lee S, Cho Y, Zi G, An J, et al.
Endocr Relat Cancer
. 2025 Feb;
32(4).
PMID: 39907208
Thyrogen, a recombinant human thyroid-stimulating hormone (rhTSH), has a short half-life in the bloodstream, which necessitates multiple doses during treatment. Therefore, we developed a new long-acting rhTSH using anti-serum albumin...
14.
Islam O, Islam O, Sarti K, Sarti K, Verbruggen L, Verbruggen L, et al.
Endocr Relat Cancer
. 2025 Jan;
32(4).
PMID: 39888333
Gastroenteropancreatic neuroendocrine neoplasms (GEP NEN) exhibit substantial biological heterogeneity, impacting clinical management and outcomes. In 2019, the WHO subdivided the grade 3 (G3) neuroendocrine neoplasms (NEN) characterised by Ki-67 >...
15.
Deng T, Liu Q, Zi H, Guo X, Huang Q, Yang Y, et al.
Endocr Relat Cancer
. 2025 Jan;
32(3).
PMID: 39878570
This study evaluated the global burden of thyroid cancer (TC) from 1990 to 2021, analyzing its association with sociodemographic factors, sex, age, risk factors and future projections. Using 2021 global...
16.
Schmidt G, Fornal I, Doerfler W, Wald A, Keating S, Nikiforova M, et al.
Endocr Relat Cancer
. 2025 Jan;
32(4).
PMID: 39878559
Approximately 10-20% of thyroid cancers are driven by gene fusions, which activate oncogenic signaling through aberrant overexpression, ligand-independent dimerization or loss of inhibitory motifs. We identified 13 thyroid tumors with...
17.
Wang S, Kidder W, Joseph N, Le B, Lindsay S, Moon F, et al.
Endocr Relat Cancer
. 2025 Jan;
32(3).
PMID: 39813097
Grade progression of well-differentiated pancreatic neuroendocrine tumors (panNETs) can occur over time, with G1/2 to G3 being the most clinically relevant form. Here, we conducted a retrospective cohort study of...
18.
Bourdeleau P, Pokossy-Epee J, Hentic O, Tihy M, Awan Z, Couvelard A, et al.
Endocr Relat Cancer
. 2025 Jan;
32(3.
PMID: 39804242
Pancreatic neuroendocrine tumours (PanNETs) have intra-tumour heterogeneity, notably regarding the Ki-67 index, which is a major prognostic factor. The temporal evolution of PanNET biology is poorly known. We aimed to...
19.
ERRATUM: Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer
Wu J, Liang J, Liu R, Lv T, Fu K, Jiang L, et al.
Endocr Relat Cancer
. 2025 Jan;
32(2.
PMID: 39798218
No abstract available.
20.
Lyman J, Dehm S
Endocr Relat Cancer
. 2025 Jan;
32(3.
PMID: 39752185
Treatment for castration-resistant prostate cancer (CRPC) primarily involves suppression of androgen receptor (AR) activity using androgen receptor signaling inhibitors (ARSIs). While ARSIs have extended patient survival, resistance inevitably develops. Mechanisms...